KDA Group Inc.

KDA

CA48669F1071

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 07:15:26 18/06/2024 pm IST			5-day change	1st Jan Change
0.3 ^CAD	+3.45%		-18.92%	+50.00%

12/06	KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer	CI
28/03	KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

KDA Group Inc. Appoints Jean-Marc Léveillé as New Member of Its Strategic Advisory Board and Consultant in Human Resources and Strategic Planning

March 10, 2022 at 01:04 am IST

KDA Group Inc. announced the addition of Mr. Jean-Marc Léveillé as a new member of its Strategic Advisory Board (the "Strategic Board") and as a consultant in human resources and strategic planning.

Latest news about KDA Group Inc.

KDA Group Inc. Announces the Development of Medherize, A New Clinical Management Solution for Specialized Medics for Breast Cancer	12/06	CI
KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	28/03	CI
KDA Group Inc. Announces an Update in the Development and Use of Its Adherize+ Platform	21/03	CI
KDA Group Inc. Announces the Appointments of Yves Marmet as General Manager and Chief Technology Officer and Marie-Hélène Pinard as Chief Operating Officer of Groupe Technologique KDA Inc	22/02	CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	20/12	CI
ZoomMed Announced Distribution to Its Shareholders of 5 Million Common Shares It Holds in KDA Group	19/12	MT
KDA Group Inc. announced that it has received CAD 1.125 million in funding	08/12	CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	28/11	CI
KDA Group Inc. Announces Executive Changes	06/23/06	CI
KDA Group Inc. acquired Substantially all the assets in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.	28/23/28	CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	07/23/07	CI
KDA Group Inc. Announces Directors Resignation	30/23/30	CI
9486-4410 Quebec Inc completed the acquisition of Agence L.I.V. Inc. from KDA Group Inc..	28/23/28	CI
ZoomMed Board Ratifies Asset Sale to KDA Group	28/23/28	MT
KDA Group Inc. entered into an agreement to acquire right, title and interest in the ZRx Prescriber from ZoomMed Medical Inc. for CAD 0.8 million.	27/23/27	CI
9486-4410 Quebec Inc entered into a share purchase agreement to acquire Agence L.I.V. Inc. from KDA Group Inc. for $13.5 million.	29/23/29	CI
Halsa Health Group Inc. entered into a share purchase agreement to acquire Élitis Pharma Inc. and Logistique Pharma Inc. from KDA Group Inc. for $2.1 million.	27/23/27	CI
KDA Group Inc. acquired Covapharm Inc for CAD 0.38 million.	21/22/21	CI
KDA Group Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	15/22/15	CI
KDA Group Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	26/22/26	CI
KDA Group Inc. Auditor Raises 'Going Concern' Doubt	25/22/25	CI
KDA Group Inc. Appoints Luc Olivier as Chief Financial Officer	19/22/19	CI
KDA Group Inc. Announces Executive Changes	30/22/30	CI
KDA Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	24/22/24	CI
KDA Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022	26/22/26	CI

KDA Group Inc. is a Canada-based solution and services provider to pharmacies and pharmaceutical companies in Canada as well as technological platform for the health industry. The Companyâs segments include Pharmacy Services, Pharmaceutical Solutions and Pharmaceutical Technology. Its Pharmacy Services segment offers training, consulting, and replacement services for professional resources in the field of healthcare. Its Pharmaceutical Solutions segment is engaged in the development and integration of technological platforms dedicated to all healthcare professionals. Its Pharmaceutical technology segment offers KRX, KRX DENTAL and ADRX platforms. It also offers ZRx Digital Prescriber an electronic prescriber computer and mobile software designed and developed for use by healthcare providers who are authorized to prescribe medications and other treatments. Its subsidiaries include Alliance Pharma Operations Inc., Elitis Pharma Inc., Logistik Pharma Inc. and Groupe Technologique KDA Inc.

Sector

Biotechnology & Medical Research

Calendar

03/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KDA GROUP INC.	+50.00%	36.99M
MODERNA, INC.	+34.58%	52.85B
IQVIA HOLDINGS INC.	-8.12%	38.87B
LONZA GROUP AG	+34.86%	38.24B
CELLTRION, INC.	-11.12%	26.79B
ICON PUBLIC LIMITED COMPANY	+12.29%	26.16B
ALNYLAM PHARMACEUTICALS, INC.	-19.38%	19.9B
UNITED THERAPEUTICS CORPORATION	+38.86%	13.18B
MEDPACE HOLDINGS, INC.	+30.44%	12.24B
BIO-TECHNE CORPORATION	-3.42%	11.79B